-- Edasalonexent Inhibits NF-kB, a Potential Driver of Disease Progression in Dysferlinopathy -- In Dysferlinopathy, muscles lack dysferlin and as a result NF-kB is chronically activated.

Catabasis Pharmaceuticals (NASDAQ:CATB) news for Tuesday includes incredibly poor results from a clinical trial hammering CATB stock hard. A Catabasis Pharmaceuticals news release reveals that the ...

As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathize with the long term shareholders of ...

Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema Company Plans to Use ...

Catabasis Pharmaceuticals, a biopharmaceutical company, has inked about $110 million in a private placement. Perceptive Advisors is the lead investor. Other investors include Fairmount Funds ...

It’s the final nail in the coffin for Catabasis Pharmaceuticals’ Duchenne muscular dystrophy (DMD) hopeful as edasalonexent has once again failed to deliver. The results look like this: The phase 3 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it has named Joseph Johnston as Vice President, ...

Multiple biological pathways go awry to cause disease. Cambridge startup Catabasis is developing a platform to simultaneously modulate multiple targets in a disease pathway, with a focus on diseases ...

Catabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after a phase 3 trial echoed the results of a failed mid-stage study. The PolarisDMD ...

Catabasis Pharma (NASDAQ:CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences. Catabasis Pharma says that its acquisition of Quellis Biosciences was on a ...

Catabasis Pharma says that its acquisition of Quellis Biosciences was on a stock-for-stock basis. This has it offering up shares of CATB stock and Series X Preferred Stock in exchange for all ...